Form 4: Acrivon CFO Reports Routine Stock Withholding

Acrivon Therapeutics' CFO, Adam D. Levy, reported the withholding of 1,164 common shares for tax obligations related to restricted stock unit vesting.

Summary

• Adam D. Levy, Chief Financial Officer of Acrivon Therapeutics, Inc. (ACRV), reported a change in beneficial ownership.
• On August 1, 2025, 1,164 shares of Acrivon Therapeutics common stock were withheld by the issuer.
• This withholding was conducted to satisfy mandatory tax requirements upon the vesting of restricted stock units.
• The shares were valued at $1.26 per share for the purpose of this tax withholding.
• Following this transaction, Mr. Levy directly beneficially owns 12,151 shares of common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine administrative transaction related to executive compensation (tax withholding upon RSU vesting) and does not indicate any significant positive or negative operational or financial developments for the company.

Positives

• The transaction reflects the vesting of restricted stock units for the Chief Financial Officer, indicating the fulfillment of compensation agreements.

Negatives

• No negative operational or financial implications are indicated by this routine administrative transaction.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it pertains to a past insider transaction.

Industry Context

This filing reports a routine insider transaction related to executive compensation, which is a common practice across industries and does not provide specific insights into broader industry trends or competitive dynamics.

Related Party Transactions

• The transaction involves the company and its Chief Financial Officer, Adam D. Levy, related to the withholding of shares for tax purposes upon the vesting of restricted stock units, which is a standard compensation practice.

Stakeholder Impact

• Minimal direct impact on shareholders, employees, customers, suppliers, or creditors, as this is a routine administrative transaction related to executive compensation.

Key Dates

Recommendation

This Form 4 filing details a routine administrative transaction where shares were withheld for tax purposes upon the vesting of restricted stock units for the Chief Financial Officer. Such transactions are standard practice for executive compensation and do not typically indicate any material change in the company's operational performance, financial health, or strategic direction. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Acrivon Therapeutics, ACRV, Adam D. Levy, CFO, Form 4, insider transaction, stock withholding, restricted stock units, RSU, beneficial ownership